Neuronascent
Clarksville, US · Maryland corporation
NeuroNascent develops therapeutics aimed at generating new neurons and regenerating existing ones to treat neurological disorders. Its R&D pipeline targets conditions including Alzheimer's disease, Parkinson's disease, and developmental delay, alongside a veterinary medicine program.
Founders & leadership
JK
Judith Kelleher-AnderssonFounder
KM
Kathleen MattisExecutive
Board
RO
Robin OegerleBoard director
MG
Maurice GagnonBoard director
Reported raises · per SEC filings
Form D private placements$1.2M disclosed across 1 round · 2015
▶$1.2MraisedMar 2015 · 1 investors · Other Health CareRule 506(b)
▶$1.2MraisedMar 2015 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robin OegerleDirector
- Maurice GagnonDirector
- Judith Kelleher-AnderssonExecutive Officer, Director
- Kathleen MattisExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1.2M
- Minimum investment
- $112.5K
- First sale
- Mar 2015
- Incorporated
- Corporation, Maryland
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Neuronascent for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Neuronascent do?
- NeuroNascent develops therapeutics aimed at generating new neurons and regenerating existing ones to treat neurological disorders. Its R&D pipeline targets conditions including Alzheimer's disease, Parkinson's disease, and developmental delay, alongside a veterinary medicine program.
- Who founded Neuronascent?
- Neuronascent was founded by Judith Kelleher-Andersson.
- How much funding has Neuronascent raised?
- Neuronascent has disclosed $1.2M raised across 1 round.
- Where is Neuronascent headquartered?
- Neuronascent is headquartered in Clarksville, US.
